

Male

PATIENT NAME: PARTE PRAVEENKUMAR GOVINDRAO REF. DOCTOR: DR. MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE (BOBE49285)

CODE/NAME & ADDRESS: C000138355 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

BASIC EYE EXAMINATION

BASIC ENT EXAMINATION

BASIC DENTAL EXAMINATION

ACCESSION NO : 0290WJ005141

PATIENT ID : PARTM150169290

CLIENT PATIENT ID: (BOBE49285)

AGE/SEX : 54 Years

DRAWN

RECEIVED: 28/10/2023 14:29:09 REPORTED :28/10/2023 18:00:40

Test Report Status Results **Biological Reference Interval** Units **Preliminary**

RESULT PENDING

RESULT PENDING

RESULT PENDING

ABHA NO

XRAY-CHEST RESULT PENDING ECG RESULT PENDING MEDICAL HISTORY RESULT PENDING ANTHROPOMETRIC DATA & BMI RESULT PENDING GENERAL EXAMINATION RESULT PENDING CARDIOVASCULAR SYSTEM RESULT PENDING RESPIRATORY SYSTEM **RESULT PENDING PER ABDOMEN RESULT PENDING CENTRAL NERVOUS SYSTEM RESULT PENDING MUSCULOSKELETAL SYSTEM RESULT PENDING**

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVR ASOUMARENDING

SUMMARY RESULT PENDING FITNESS STATUS RESULT PENDING

Page 1 Of 12







Patient Ref. No. 775000005256045



PATIENT NAME: PARTE PRAVEENKUMAR GOVINDRAO
(BOBE49285)

REF. DOCTOR: DR. MEDI WHEEL FULL BODY HEALTH CHECK
UP ABOVE 40 MALE

CODE/NAME & ADDRESS : C000138355

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156 ACCESSION NO : 0290WJ005141

PATIENT ID : PARTM150169290

CLIENT PATIENT ID: (BOBE49285)

ABHA NO :

AGE/SEX : 54 Years

DRAWN :

Male

RECEIVED : 28/10/2023 14:29:09 REPORTED : 28/10/2023 18:00:40

Test Report Status Preliminary Results Units

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVR EXQUIRATER DING
ULTRASOUND ABDOMEN RESULT PENDING
TMT OR ECHO RESULT PENDING

Page 2 Of 12





View Details

View Report





PATIENT NAME: PARTE PRAVEENKUMAR GOVINDRAO REF. DOCTOR: DR. MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE (BOBE49285)

CODE/NAME & ADDRESS: C000138355 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

ACCESSION NO : 0290WJ005141

PATIENT ID : PARTM150169290

CLIENT PATIENT ID: (BOBE49285)

ABHA NO

AGE/SEX :54 Years

DRAWN

Male

RECEIVED: 28/10/2023 14:29:09

REPORTED :28/10/2023 18:00:40

Results **Biological Reference Interval Test Report Status Preliminary** Units

| HAEMATOLOGY - CBC | | | |
|--|--------------|-------------|---------|
| MEDI WHEEL FULL BODY HEALTH CHECK UP A | BOVE 40 MALE | | |
| BLOOD COUNTS,EDTA WHOLE BLOOD | | | |
| HEMOGLOBIN (HB) | 14.5 | 13.0 - 17.0 | g/dL |
| RED BLOOD CELL (RBC) COUNT | 5.40 | 4.5 - 5.5 | mil/μL |
| WHITE BLOOD CELL (WBC) COUNT | 6.31 | 4.0 - 10.0 | thou/µL |
| PLATELET COUNT | 331 | 150 - 410 | thou/µL |
| RBC AND PLATELET INDICES | | | |
| HEMATOCRIT (PCV) | 41.9 | 40 - 50 | % |
| MEAN CORPUSCULAR VOLUME (MCV) | 77.6 Low | 83 - 101 | fL |
| MEAN CORPUSCULAR HEMOGLOBIN (MCH) | 26.9 Low | 27.0 - 32.0 | pg |
| MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) | 34.6 High | 31.5 - 34.5 | g/dL |
| RED CELL DISTRIBUTION WIDTH (RDW) | 15.9 High | 11.6 - 14.0 | % |
| MENTZER INDEX | 14.4 | | |
| MEAN PLATELET VOLUME (MPV) | 7.5 | 6.8 - 10.9 | fL |
| WBC DIFFERENTIAL COUNT | | | |
| NEUTROPHILS | 53 | 40 - 80 | % |
| LYMPHOCYTES | 35 | 20 - 40 | % |
| MONOCYTES | 07 | 2 - 10 | % |
| EOSINOPHILS | 05 | 1 - 6 | % |
| BASOPHILS | 00 | 0 - 2 | % |
| ABSOLUTE NEUTROPHIL COUNT | 3.34 | 2.0 - 7.0 | thou/µL |
| ABSOLUTE LYMPHOCYTE COUNT | 2.21 | 1 - 3 | thou/µL |
| ABSOLUTE MONOCYTE COUNT | 0.44 | 0.20 - 1.00 | thou/µL |
| ABSOLUTE EOSINOPHIL COUNT | 0.32 | 0.02 - 0.50 | thou/µL |

Interpretation(s)
BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive

Dr. Arpita Pasari, MD **Consultant Pathologist**





Page 3 Of 12





PATIENT NAME: PARTE PRAVEENKUMAR GOVINDRAO REF. DOCTOR: DR. MEDI WHEEL FULL BODY HEALTH CHECK

UP ABOVE 40 MALE (BOBE49285)

CODE/NAME & ADDRESS: C000138355 ACCESSION NO : 0290WJ005141 AGE/SEX : 54 Years Male

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID DRAWN : PARTM150169290 F-703, LADO SARAI, MEHRAULISOUTH WEST

CLIENT PATIENT ID: (BOBE49285) RECEIVED : 28/10/2023 14:29:09 DELHI REPORTED :28/10/2023 18:00:40 ABHA NO **NEW DELHI 110030**

Test Report Status Results **Biological Reference Interval Preliminary** Units

Dr.Arpita Pasari, MD **Consultant Pathologist**





Page 4 Of 12





REF. DOCTOR: DR. MEDI WHEEL FULL BODY HEALTH CHECK **PATIENT NAME: PARTE PRAVEENKUMAR GOVINDRAO**

CLIENT PATIENT ID: (BOBE49285)

UP ABOVE 40 MALE (BOBE49285)

CODE/NAME & ADDRESS: C000138355 ACCESSION NO : 0290WJ005141 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : PARTM150169290

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030

8800465156

AGE/SEX : 54 Years Male

DRAWN

RECEIVED: 28/10/2023 14:29:09 REPORTED :28/10/2023 18:00:40

Biological Reference Interval Test Report Status Results Units <u>Preliminary</u>

ABHA NO

HAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD

FSR 0 - 14mm at 1 hr 06

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE **BLOOD**

6.7 High Non-diabetic: < 5.7 % HBA1C

> Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5Therapeutic goals: < 7.0Action suggested : > 8.0 (ADA Guideline 2021)

ESTIMATED AVERAGE GLUCOSE(EAG) 145.6 High < 116.0 mg/dL

Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change **TEST INTERPRETATION**

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias,

Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine,

salicylates)

REFERENCE:

- . Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:
- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- Diagnosing diabetes.

3. Identifying patients at increased risk for diabetes (prediabetes).
The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

Dr. Arpita Pasari, MD **Consultant Pathologist**





Page 5 Of 12

View Report





REF. DOCTOR: DR. MEDI WHEEL FULL BODY HEALTH CHECK **PATIENT NAME: PARTE PRAVEENKUMAR GOVINDRAO**

UP ABOVE 40 MALE (BOBE49285)

CODE/NAME & ADDRESS: C000138355 ACCESSION NO : 0290WJ005141 AGE/SEX :54 Years Male

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID DRAWN : PARTM150169290

F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: (BOBE49285) RECEIVED: 28/10/2023 14:29:09 DELHI ABHA NO REPORTED :28/10/2023 18:00:40 NEW DELHI 110030

Results **Biological Reference Interval Test Report Status Preliminary** Units

eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.
 eAG gives an evaluation of blood glucose levels for the last couple of months.

3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c - 46.7

HbA1c Estimation can get affected due to :

- 1. Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss,hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.
- 2.Vitamin C & E are reported to falsely lower test results.(possibly by inhibiting glycation of hemoglobin.
 3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.
- 4. Interference of hemoglobinopathies in HbA1c estimation is seen in
- a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
- b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
 c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

Dr. Arpita Pasari, MD **Consultant Pathologist**



Page 6 Of 12

View Report





PATIENT NAME: PARTE PRAVEENKUMAR GOVINDRAO REF. DOCTOR: DR. MEDI WHEEL FULL BODY HEALTH CHECK

UP ABOVE 40 MALE (BOBE49285)

CODE/NAME & ADDRESS: C000138355 ACCESSION NO : 0290WJ005141 :54 Years AGE/SEX Male

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID DRAWN : PARTM150169290

F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: (BOBE49285) RECEIVED: 28/10/2023 14:29:09

DELHI ABHA NO REPORTED :28/10/2023 18:00:40 **NEW DELHI 110030**

Results **Biological Reference Interval Test Report Status Preliminary** Units

IMMUNOHAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP TYPE AB RH TYPE **POSITIVE**

8800465156

Interpretation(s)
ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.

The test is performed by both forward as well as reverse grouping methods.

Dr. Arpita Pasari, MD **Consultant Pathologist**





Page 7 Of 12





PATIENT NAME: PARTE PRAVEENKUMAR GOVINDRAO REF. DOCTOR: DR. MEDI WHEEL FULL BODY HEALTH CHECK

UP ABOVE 40 MALE (BOBE49285)

CODE/NAME & ADDRESS: C000138355 ACCESSION NO : 0290WJ005141 AGE/SEX : 54 Years Male

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID DRAWN : PARTM150169290

F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: (BOBE49285) RECEIVED: 28/10/2023 14:29:09 DELHI

REPORTED :28/10/2023 18:00:40 ABHA NO **NEW DELHI 110030**

Results **Biological Reference Interval Test Report Status Preliminary** Units

BIOCHEMISTRY

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

| GLUCOSE | FASTING | FILIORIDE | ΟΙ Δ SΜΔ |
|---------|---------|-----------|----------|

| FBS (FASTING BLOOD SUGAR) | 121 High | 74 - 99 | mg/dL |
|---------------------------|----------|---------|-------|

GLUCOSE, POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR) mg/dL 124 Normal: < 140,

> Impaired Glucose Tolerance: 140-199 Diabetic > or = 200

LIPID PROFILE WITH CALCULATED LDL

CHOLESTEROL, TOTAL 193 Desirable: <200 mg/dL

BorderlineHigh: 200-239 High: > or = 240

TRIGLYCERIDES 109 Desirable: < 150 mg/dL

Borderline High: 150 - 199

High: 200 - 499 Very High: > or = 500

HDL CHOLESTEROL 35 Low < 40 Low mg/dL

> or = 60 High

CHOLESTEROL LDL 136 High mg/dL Adult levels:

Optimal < 100

Near optimal/above optimal:

100-129

Borderline high: 130-159

High: 160-189 Very high: = 190

NON HDL CHOLESTEROL 158 High Desirable: Less than 130 ma/dL

Above Desirable: 130 - 159 Borderline High: 160 - 189

High: 190 - 219

Very high: > or = 220

< or = 30

mg/dL VERY LOW DENSITY LIPOPROTEIN 21.8

5.5 High CHOL/HDL RATIO 3.3 - 4.4

LDL/HDL RATIO 3.9 High 0.5 - 3.0 Desirable/Low Risk

3.1 - 6.0 Borderline/Moderate

Risk

>6.0 High Risk

Dr. Arpita Pasari, MD **Consultant Pathologist**



Page 8 Of 12





Male

PATIENT NAME: PARTE PRAVEENKUMAR GOVINDRAO
(BOBE49285)

REF. DOCTOR: DR. MEDI WHEEL FULL BODY HEALTH CHECK
UP ABOVE 40 MALE

CODE/NAME & ADDRESS : C000138355
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL

F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156 ACCESSION NO : 0290WJ005141

PATIENT ID : PARTM150169290

CLIENT PATIENT ID: (BOBE49285) ABHA NO : AGE/SEX : 54 Years

DRAWN :

RECEIVED : 28/10/2023 14:29:09

REPORTED :28/10/2023 18:00:40

| Test Report Status <u>Preliminary</u> | Results | Biological Reference Interv | al Units |
|---------------------------------------|-----------|-----------------------------|----------|
| LIVER FUNCTION PROFILE, SERUM | | | |
| BILIRUBIN, TOTAL | 0.57 | 0.0 - 1.2 | mg/dL |
| BILIRUBIN, DIRECT | 0.24 High | 0.0 - 0.2 | mg/dL |
| BILIRUBIN, INDIRECT | 0.33 | 0.00 - 1.00 | mg/dL |
| TOTAL PROTEIN | 7.7 | 6.4 - 8.3 | g/dL |
| ALBUMIN | 4.7 | 3.50 - 5.20 | g/dL |
| GLOBULIN | 3.0 | 2.0 - 4.1 | g/dL |
| ALBUMIN/GLOBULIN RATIO | 1.6 | 1.0 - 2.0 | RATIO |
| ASPARTATE AMINOTRANSFERASE(AST/SGOT) | 19 | UPTO 40 | U/L |
| ALANINE AMINOTRANSFERASE (ALT/SGPT) | 19 | UP TO 45 | U/L |
| ALKALINE PHOSPHATASE | 47 | 40 - 129 | U/L |
| GAMMA GLUTAMYL TRANSFERASE (GGT) | 25 | 8 - 61 | U/L |
| LACTATE DEHYDROGENASE | 171 | 135 - 225 | U/L |
| BLOOD UREA NITROGEN (BUN), SERUM | | | |
| BLOOD UREA NITROGEN | 8 | 6 - 20 | mg/dL |
| CREATININE, SERUM | | | |
| CREATININE | 0.87 | 0.70 - 1.20 | mg/dL |
| BUN/CREAT RATIO | | | |
| BUN/CREAT RATIO | 9.20 | 5.0 - 15.0 | |
| URIC ACID, SERUM | | | |
| URIC ACID | 5.9 | 3.5 - 7.2 | mg/dL |
| TOTAL PROTEIN, SERUM | | | |
| TOTAL PROTEIN | 7.7 | 6.4 - 8.3 | g/dL |
| ALBUMIN, SERUM | | | |
| ALBUMIN | 4.7 | 3.5 - 5.2 | g/dL |
| GLOBULIN | | | |
| GLOBULIN | 3.0 | 2.0 - 4.1 | g/dL |
| ELECTROLYTES (NA/K/CL), SERUM | | | |
| SODIUM, SERUM | 138.5 | 136.0 - 146.0 | mmol/L |
| POTASSIUM, SERUM | 4.09 | 3.50 - 5.10 | mmol/L |
| CHLORIDE, SERUM | 101.6 | 98.0 - 106.0 | mmol/L |

Pepita

Dr.Arpita Pasari, MD Consultant Pathologist





Page 9 Of 12

View Details

View Report





Male

REF. DOCTOR: DR. MEDI WHEEL FULL BODY HEALTH CHECK **PATIENT NAME: PARTE PRAVEENKUMAR GOVINDRAO** UP ABOVE 40 MALE (BOBE49285)

CODE/NAME & ADDRESS: C000138355 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156

ACCESSION NO : 0290WJ005141 AGE/SEX : 54 Years

PATTENT ID : PARTM150169290

CLIENT PATIENT ID: (BOBE49285)

ABHA NO

DRAWN

RECEIVED: 28/10/2023 14:29:09 REPORTED :28/10/2023 18:00:40

Test Report Status Results **Biological Reference Interval** Units <u>Preliminary</u>

Interpretation(s)

GLUCOSE FASTING FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the

Increased in:Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides. Decreased in : Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical in sufficiency, hypopituitarism, diffuse liver disease, malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol sulfonylureas,tolbutamide,and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals.Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic

index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys,heart,muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine. spleen heart. brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin.Higher-than-normal levels may be due to: Chronic inflammation or infection,including HIV and hepatitis B or C,Multiple myeloma,Waldenstroms disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease, Malabsorption,Malnutrition,Nephrotic

syndrome, Protein-losing enteropathy etc. **Albumin** is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by:Liver disease like cirrhosis of the liver, nephrotic syndrome,protein-losing enteropathy,Burns,hemodilution,increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc

BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to:

• Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:• Myasthenia Gravis, Muscuophy

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic

syndrome Causes of decreased levels-Low Zinc intake,OCP,Multiple Sclerosis

TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum.Protein in the plasma is made up of albumin and globulin.

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma,Waldenstroms diseased. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

Dr. Arpita Pasari, MD Consultant Pathologist Page 10 Of 12





View Details

View Report





PATIENT NAME: PARTE PRAVEENKUMAR GOVINDRAO

REF. DOCTOR: DR. MEDI WHEEL FULL BODY HEALTH CHECK

(BOBE49285) UP ABOVE 40 MALE

CODE/NAME & ADDRESS : C000138355 ACCESSION NO : **0290WJ005141** AGE/SEX : 54 Years Male

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL PATIENT ID : PARTM150169290 DRAWN :

F-703, LADO SARAI, MEHRAULISOUTH WEST CLIENT PATIENT ID: (BOBE49285) RECEIVED: 28/10/2023 14:29:09

Test Report Status <u>Preliminary</u> Results Biological Reference Interval Units

CLINICAL PATH - URINALYSIS

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

PHYSICAL EXAMINATION, URINE

COLOR PALE YELLOW

APPEARANCE CLEAR

CHEMICAL EXAMINATION, URINE

5.0 4.7 - 7.5SPECIFIC GRAVITY 1.015 1.003 - 1.035 **PROTEIN** NOT DETECTED NOT DETECTED **GLUCOSE** NOT DETECTED NOT DETECTED **KETONES** NOT DETECTED NOT DETECTED BLOOD NOT DETECTED NOT DETECTED **BILIRUBIN** NOT DETECTED NOT DETECTED **UROBILINOGEN NORMAL NORMAL NITRITE** NOT DETECTED NOT DETECTED LEUKOCYTE ESTERASE NOT DETECTED NOT DETECTED

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS

NOT DETECTED

NOT DETECTED

/HPF

PUS CELL (WBC'S)

2-3

0-5

/HPF

EPITHELIAL CELLS

2-3

0-5

/HPF

CASTS NOT DETECTED
CRYSTALS NOT DETECTED

BACTERIA NOT DETECTED NOT DETECTED
YEAST NOT DETECTED NOT DETECTED

REMARKS .Please note that all the urinary findings are confirmed manually as well.

Dr.Arpita Pasari, MD Consultant Pathologist Page 11 Of 12













PATIENT NAME: PARTE PRAVEENKUMAR GOVINDRAO
(BOBE49285)

REF. DOCTOR: DR. MEDI WHEEL FULL BODY HEALTH CHECK
UP ABOVE 40 MALE

CODE/NAME & ADDRESS : C000138355

ARCOFEMI HEALTHCARE LTD (MEDIWHEEL
F-703, LADO SARAI, MEHRAULISOUTH WEST

DELHI

NEW DELHI 110030 8800465156 ACCESSION NO: 0290WJ005141

PATIENT ID : PARTM150169290

CLIENT PATIENT ID: (BOBE49285)

ABHA NO :

AGE/SEX : 54 Years

ars

Male

DRAWN :

RECEIVED : 28/10/2023 14:29:09 REPORTED : 28/10/2023 18:00:40

Test Report Status <u>Preliminary</u> Results Biological Reference Interval Units

SPECIALISED CHEMISTRY - HORMONE

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

THYROID PANEL, SERUM

| ТЗ | 120.90 | 80.0 - 200.0 | ng/dL |
|----------------------|--------|---------------|--------|
| T4 | 8.10 | 5.10 - 14.10 | μg/dL |
| TSH (ULTRASENSITIVE) | 3.270 | 0.270 - 4.200 | μIU/mL |

End Of Report
Please visit www.agilusdiagnostics.com for related Test Information for this accession

CONDITIONS OF LABORATORY TESTING & REPORTING

- 1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
- 2. All tests are performed and reported as per the
- turnaround time stated in the AGILUS Directory of Services.
- 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
- 4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type
 - iv. Discrepancy between identification on specimen container label and test requisition form

- 5. AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- 6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
- 7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
- 8. Test results cannot be used for Medico legal purposes.
- 9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

Agilus Diagnostics Ltd

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

Proita

Dr.Arpita Pasari, MD Consultant Pathologist





Page 12 Of 12

View Details

View Report

Tel: 0731 2490008

Patient Ref. No. 775000005256045